Amyris expands precision fermentation line in Brazil

Ingredion will have exclusive access to Amyris’ technology to manufacture and sell fermented Reb M

Zydus receives tentative approval from USFDA for Rifaximin Tablets, 550 mg

Rifaximin tablets had annual sales of US$ 2672.9 mn in the United States (IQVIA MAT March 2025)

SeQuent–Viyash merger receives stock exchange approvals; NCLT filing underway

Piramal Pharma completes USFDA inspection of Aurora facility with Zero Form-483 observations

Merck withdraws Biologics License Application for Patritumab Deruxtecan

The decision to withdraw the BLA is based on topline overall survival (OS) results from the confirmatory HERTHENA-Lung02 Phase 3 trial where OS did not meet statistical significance

Sanjivani Paranteral posts Q4 FY25 at Rs. 2.19 Cr

For FY25, Revenue from operation grew 28.8 per cent YoY to Rs. 70.1 crore

Fluor-built Bayer cell therapy facility in California achieves LEED v4 platinum certification

Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs

Akums reports Q4 FY25 with 12.4% revenue growth

Akums invested Rs. 272 crore in capital expenditure during FY25

Kilitch Drugs posts consolidated Q4 FY25 PAT at Rs. 10.21 Cr

The company recorded its quarterly consolidated revenue from operations at Rs. 61.22 crore in Q4 FY25

Lupin and SteinCares ink agreement for Ranibizumab in Latin America

Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A